Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YAEL RACHEL ELFASSY

Allopathic & Osteopathic Physicians Pediatrics

NPI
1598081002
CMS profile
253025
Location
SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$31.57

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $31.57 2

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $31.57 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YAEL RACHEL ELFASSY

NPI 1598081002 · CMS profile ID 253025

Allopathic & Osteopathic Physicians / Pediatrics

SAVANNAH, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $31.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $17.4208/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937307117 CMS
SANOFI PASTEUR INC. $14.1504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937307105 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $31.57 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,633.80 124
PY2024 Principal investigator $942,634.71 86
PY2023 Recipient $511.38 1
PY2023 Principal investigator $550,439.29 47
PY2022 Principal investigator $196,273.44 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $381.00 12/31/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 998414409
Principal investigator 1 Corium, LLC $4,859.63 12/28/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/? Azstarys in Children With ADHD No dispute reported 06/30/2026 987458049
Principal investigator 1 PFIZER INC. $6,496.00 12/14/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046306365
Principal investigator 1 Eli Lilly and Company $143.88 12/08/2023 Non-covered Recipient Entity
ADVOCARE BERLIN MEDICAL ASSOCIATES
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038083687
Principal investigator 1 Corium, LLC $15,525.00 12/07/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD No dispute reported 06/30/2026 987458081
Principal investigator 1 PFIZER INC. $403.92 12/07/2023 Non-covered Recipient Entity
CenExel iResearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046088783
Principal investigator 1 ModernaTX, Inc. $8,000.00 12/06/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041770799
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/06/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041771223
Principal investigator 1 ModernaTX, Inc. $2,624.40 12/06/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1041771231
Principal investigator 1 ABBVIE INC. $7,500.00 12/04/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 998409865
Principal investigator 1 Corium, LLC $12,334.51 11/02/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/? Azstarys in Children With ADHD No dispute reported 06/30/2026 987458047
Principal investigator 1 ModernaTX, Inc. $5,676.75 10/27/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041771205
Principal investigator 1 PFIZER INC. $403.92 09/06/2023 Non-covered Recipient Entity
CenExel iResearch Savannah IRS
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045985727
Principal investigator 1 ModernaTX, Inc. $2,577.00 09/01/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041770583
Principal investigator 1 ModernaTX, Inc. $8,500.00 09/01/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 1041771199
Principal investigator 1 Corium, LLC $61,672.55 08/30/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/? Azstarys in Children With ADHD No dispute reported 06/30/2026 987457951
Principal investigator 1 PFIZER INC. $500.08 08/22/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046222907
Principal investigator 1 PFIZER INC. $5,000.80 08/09/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046222989
Principal investigator 1 ModernaTX, Inc. $2,066.35 08/04/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771193
Principal investigator 1 PFIZER INC. $500.08 07/19/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046121669
Principal investigator 1 Eli Lilly and Company $212,427.00 07/18/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038074271
Principal investigator 1 PFIZER INC. $3,000.48 06/22/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046159705
Principal investigator 1 ModernaTX, Inc. $605.15 06/21/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771187
Principal investigator 1 PFIZER INC. $2,000.32 06/16/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046333159
Principal investigator 1 PFIZER INC. $1,000.16 06/14/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045955609
Principal investigator 1 PFIZER INC. $25,004.00 06/03/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046063877
Principal investigator 1 PFIZER INC. $500.08 05/25/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046100093
Principal investigator 1 ModernaTX, Inc. $605.15 05/24/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771175
Principal investigator 1 Corium, LLC $10,500.00 05/03/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
An Efficacy and Safety Study w/? Azstarys in Children With ADHD No dispute reported 06/30/2026 987457887
Principal investigator 1 ModernaTX, Inc. $605.15 04/26/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771169
Principal investigator 1 ModernaTX, Inc. $2,000.70 04/19/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771163
Principal investigator 1 ModernaTX, Inc. $605.15 04/03/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771159
Principal investigator 1 Amgen Inc. $9,126.00 03/25/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 1029657945
Principal investigator 1 Eli Lilly and Company $443.50 03/16/2023 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038076789
Principal investigator 1 PFIZER INC. $1,500.24 03/09/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045998223
Principal investigator 1 ModernaTX, Inc. $9,610.00 03/08/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771181
Principal investigator 1 PFIZER INC. $2,000.32 03/07/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045897633
Principal investigator 1 PFIZER INC. $26,004.16 03/04/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046153433
Principal investigator 1 ModernaTX, Inc. $605.15 03/01/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771153
Recipient Eli Lilly and Company $511.38 02/17/2023 Covered Recipient Physician A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038057801
Principal investigator 1 PFIZER INC. $19,527.84 02/10/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046295777
Principal investigator 1 ModernaTX, Inc. $3,057.08 02/08/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041771145
Principal investigator 1 PFIZER INC. $6,509.28 02/07/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046016445
Principal investigator 1 Amgen Inc. $21,040.60 02/02/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 1029657951
Principal investigator 1 Amgen Inc. $36,544.20 01/26/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1029656329
Principal investigator 1 ModernaTX, Inc. $262.20 01/13/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041770577
Principal investigator 1 PFIZER INC. $6,509.28 01/12/2023 Non-covered Recipient Entity
CenExel iReasearch LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045997223
Principal investigator 1 ModernaTX, Inc. $2,180.23 01/11/2023 Non-covered Recipient Entity
IRESEARCH SAVANNAH LLC
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1041770571